JP2004525150A5 - - Google Patents

Download PDF

Info

Publication number
JP2004525150A5
JP2004525150A5 JP2002576967A JP2002576967A JP2004525150A5 JP 2004525150 A5 JP2004525150 A5 JP 2004525150A5 JP 2002576967 A JP2002576967 A JP 2002576967A JP 2002576967 A JP2002576967 A JP 2002576967A JP 2004525150 A5 JP2004525150 A5 JP 2004525150A5
Authority
JP
Japan
Prior art keywords
alkyl
group
aryl
heterocyclyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002576967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525150A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/008621 external-priority patent/WO2002078701A1/en
Publication of JP2004525150A publication Critical patent/JP2004525150A/ja
Publication of JP2004525150A5 publication Critical patent/JP2004525150A5/ja
Withdrawn legal-status Critical Current

Links

JP2002576967A 2001-03-30 2002-03-20 治療用化合物としてのピラゾロピリジン類の使用 Withdrawn JP2004525150A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28004701P 2001-03-30 2001-03-30
US30718901P 2001-07-23 2001-07-23
PCT/US2002/008621 WO2002078701A1 (en) 2001-03-30 2002-03-20 Use of pyrazolopyridines as therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2004525150A JP2004525150A (ja) 2004-08-19
JP2004525150A5 true JP2004525150A5 (enExample) 2005-12-22

Family

ID=26960034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002576967A Withdrawn JP2004525150A (ja) 2001-03-30 2002-03-20 治療用化合物としてのピラゾロピリジン類の使用

Country Status (4)

Country Link
US (1) US20050107400A1 (enExample)
EP (1) EP1372642A1 (enExample)
JP (1) JP2004525150A (enExample)
WO (1) WO2002078701A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1377573B1 (en) * 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
ES2266487T3 (es) * 2001-04-10 2007-03-01 Smithkline Beecham Corporation Compuestos de pirazolopirina antivirales.
DE60220525T2 (de) * 2001-09-07 2008-02-07 Smithkline Beecham Corp. Pyrazolo-pyridine für die behandlung von herpes-ansteckungen
DE60301339T2 (de) * 2002-03-07 2006-03-09 Smithkline Beecham Corp. Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004033454A1 (en) * 2002-10-03 2004-04-22 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
US7087755B1 (en) * 2004-11-12 2006-08-08 Frontier Scientific, Inc. Substituted pyridines
US7485725B1 (en) 2004-11-12 2009-02-03 Frontier Scientific, Inc. Substituted pyridines
WO2006055245A2 (en) * 2004-11-17 2006-05-26 Smithkline Beecham Corporation Process for preparing pyrazolopyridine compounds
KR101054325B1 (ko) 2006-03-31 2011-08-04 얀센 파마슈티카 엔.브이. 히스타민 h4 수용체 조절제로서의 벤조이미다졸―2―일 피리미딘 및 피라진
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2310012B1 (en) 2008-06-30 2015-03-04 Janssen Pharmaceutica N.V. Process for the preparation of substituted pyrimidine derivatives
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8293909B2 (en) 2008-09-11 2012-10-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2012527461A (ja) * 2009-05-19 2012-11-08 ダウ アグロサイエンシィズ エルエルシー 真菌を防除するための化合物および方法
TW201102387A (en) * 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
US8324212B2 (en) 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8354410B2 (en) 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
AR081810A1 (es) * 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションIncyte Corporation PI3Kδ阻害剤としての縮合誘導体
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2402335A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402336A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
MY179332A (en) 2011-09-02 2020-11-04 Incyte Holdings Corp Heterocyclylamines as pl3k inhibitors
ES2632584T3 (es) * 2011-10-06 2017-09-14 Bayer Intellectual Property Gmbh Heterociclilpiri(mi)dinilpirazol
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
HRP20200253T1 (hr) 2013-03-06 2020-05-29 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
EP3831833B1 (en) 2015-02-27 2022-10-26 Incyte Holdings Corporation Processes for the preparation of a pi3k inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2017207358A1 (en) 2016-06-03 2017-12-07 Basf Se Benzoxaborole compounds
BR112019008661A2 (pt) 2016-11-28 2019-07-09 Basf Se composto de diaminotriazina, composição agroquímica, método para o controle da vegetação indesejada e utilização do composto
US11058117B2 (en) 2017-11-22 2021-07-13 Basf Se Benzoxaborole compounds
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
US11992012B2 (en) 2018-09-18 2024-05-28 Basf Se Diaminotriazine compounds
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
AU2020328025A1 (en) 2019-08-14 2022-03-03 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
JOP20220087A1 (ar) 2019-10-11 2023-01-30 Incyte Corp أمينات ثنائية الحلقة كمثبطات لـ cdk2
AU2022214122A1 (en) 2021-01-27 2023-08-10 Basf Se Diaminotriazine compounds
CA3205911A1 (en) 2021-01-27 2022-08-04 Danny GEERDINK Diaminotriazine compounds
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151962A3 (en) * 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
GB8404586D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
GB8404584D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
AU622330B2 (en) * 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5300478A (en) * 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CA2224517A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
FR2757166B1 (fr) * 1996-12-12 1999-01-29 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
EP1377573B1 (en) * 2000-12-15 2005-07-27 Glaxo Group Limited Pyrazolopyridine derivatives
EP1366048B1 (en) * 2001-03-08 2004-08-25 SmithKline Beecham Corporation Pyrazolopyridine derivatives

Similar Documents

Publication Publication Date Title
JP2004525150A5 (enExample)
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
JP2004506736A5 (enExample)
JP2020037585A5 (enExample)
EP4458834A3 (en) Heterocyclic glp-1 agonists
CY1117459T1 (el) Παραγωγα που εχουν δραση αγωνιστη του βητα-2 αδρενεργικου υποδοχεα και ανταγωνιστη του μουσκαρινικου υποδοχεα
JP2018507890A5 (enExample)
JP2006517939A5 (enExample)
JP2009542716A5 (enExample)
JP2005523922A5 (enExample)
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
JP2004520324A5 (enExample)
JP2020507589A5 (enExample)
JP2009519243A5 (enExample)
JP2004175807A5 (enExample)
JP2018509418A5 (enExample)
JP2020500182A5 (enExample)
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
ATE450533T1 (de) Carboxamidderivate
JP2018516904A5 (enExample)
JP2019535723A5 (enExample)
JP2015508092A5 (enExample)
JP2007505931A5 (enExample)
JP2007520440A5 (enExample)
JP2007510662A5 (enExample)